{"id":538083,"date":"2021-04-12T17:22:01","date_gmt":"2021-04-12T17:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=538083"},"modified":"2021-04-12T17:22:01","modified_gmt":"2021-04-12T17:22:01","slug":"fibrodysplasia-ossificans-progressiva-fop-competitive-landscape2020-emerging-therapies-and-key-pharma-players-involved","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fibrodysplasia-ossificans-progressiva-fop-competitive-landscape2020-emerging-therapies-and-key-pharma-players-involved_538083.html","title":{"rendered":"Fibrodysplasia Ossificans Progressiva (FOP) Competitive Landscape,2020: Emerging therapies and key pharma players involved"},"content":{"rendered":"
\"Fibrodysplasia<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, Fibrodysplasia Ossificans Progressiva (FOP) Pipeline Insights, 2021, report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in the Fibrodysplasia Ossificans Progressiva pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<\/div>\n

Fibrodysplasia Ossificans Progressiva (FOP) Pipeline Insight, 2020<\/strong><\/a> report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Fibrodysplasia Ossificans Progressiva (FOP) market. A detailed picture of the Fibrodysplasia Ossificans Progressiva (FOP) pipeline landscape is provided, which includes the disease overview and Fibrodysplasia Ossificans Progressiva (FOP) treatment guidelines.<\/p>\n

About the Disease:<\/strong><\/p>\n

Fibrodysplasia ossificans progressiva (FOP) <\/strong><\/a>is a disorder in which muscle and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. This process generally becomes noticeable in early childhood, starting with the neck and shoulders, and proceeding down the body and into the limbs.<\/p>\n

Mutations in the ACVR1 gene causes fibrodysplasia ossificans progressiva. The underlying genetic mutation in FOP alters the signals that regulate the induction of cell differentiation leading to bone formation.<\/p>\n

The symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restriction of motion at various joints, severely limiting the activities of daily living and the quality of life of such patients by the third decade of life.<\/p>\n

Extra-skeletal bone formation causes a progressive loss of mobility as the joints become affected. Inability to fully open the mouth may cause difficulty in speaking and eating. Over time, people with this disorder may experience malnutrition due to their eating problems. They may also have breathing difficulties as a result of extra bone formation around the rib cage that restricts expansion of the lungs.<\/p>\n

The key players in the Fibrodysplasia Ossificans Progressiva market are:<\/strong><\/p>\n

1. Ipsen
2. Regeneron Pharmaceuticals
3. BioCryst
4. Keros Therapeutics
and many others <\/p>\n

The launch of the emerging therapies is expected to significantly impact Fibrodysplasia Ossificans Progressiva treatment scenario in the upcoming years:-<\/strong>
Drugs covered<\/strong>
1. Palovarotene
2. Garetosmab (REGN2477)
3. BLU-782
4. BCX9250
5. KER-047
and many others<\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight<\/a><\/strong><\/p>\n

Scope of the report:<\/strong>
<\/strong>1. The Fibrodysplasia Ossificans Progressiva (FOP) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Fibrodysplasia Ossificans Progressiva (FOP) across the complete product development cycle, including all clinical and nonclinical stages.
2. It comprises of detailed profiles of Fibrodysplasia Ossificans Progressiva (FOP) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
3. Detailed Fibrodysplasia Ossificans Progressiva (FOP) research and development progress and trial details, results wherever available, are also included in the pipeline study.
4. Coverage of dormant and discontinued pipeline projects along with the reasons if available across Fibrodysplasia Ossificans Progressiva (FOP).<\/p>\n

Table of contents:<\/strong>
1. Report Introduction
2. Fibrodysplasia Ossificans Progressiva (FOP) 
3. Fibrodysplasia Ossificans Progressiva (FOP) Current Treatment Patterns
4. Fibrodysplasia Ossificans Progressiva (FOP) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Fibrodysplasia Ossificans Progressiva (FOP) Late Stage Products (Phase-III)
7. Fibrodysplasia Ossificans Progressiva (FOP) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fibrodysplasia Ossificans Progressiva (FOP) Discontinued Products
13. Fibrodysplasia Ossificans Progressiva (FOP) Product Profiles
14. Fibrodysplasia Ossificans Progressiva (FOP) Key Companies
15. Fibrodysplasia Ossificans Progressiva (FOP) Key Products
16. Dormant and Discontinued Products
17. Fibrodysplasia Ossificans Progressiva (FOP) Unmet Needs
18. Fibrodysplasia Ossificans Progressiva (FOP) Future Perspectives
19. Fibrodysplasia Ossificans Progressiva (FOP) Analyst Review  
20. Appendix
21. Report Methodology<\/p>\n

Download free sample pages: https:\/\/www.delveinsight.com\/sample-request\/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight<\/a><\/strong><\/p>\n

About DelveInsight:<\/strong>
<\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s, Fibrodysplasia Ossificans Progressiva (FOP) Pipeline Insights, 2021, report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in the Fibrodysplasia Ossificans Progressiva pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-538083","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=538083"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538083\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=538083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=538083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=538083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}